BioSpace News Archive

Enzyvant announced it is among the National Organization for Rare Disorders 2022 Industry Innovation Awards recipients for the development and U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for pediatric congenital athymia.

NextCure, Inc. presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the “Board”), effective June 23, 2022.

Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), today announced that data on its lead compound CPI-613® (devimistat) in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer will be presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) .

Maravai LifeSciences, Inc. announced that Peter Leddy, Ph.D. has joined the Company as Executive Vice President and Chief Administrative Officer.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer patients (Part B) in the Phase II TACTI-002 trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer.

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer.

Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Gregory S. Moss, Esq. , as chief corporate strategy and legal officer.

Proceeds will accelerate a robust R&D pipeline, commercial partnerships and clinical activities led by leading institutional and strategic investors.